Compare
Alpha Cognition Inc. vs Lineage Cell Therapeutics, Inc. vs Pelthos Therapeutics Inc. vs LENZ Therapeutics, Inc.
| Latest fiscal year | Alpha Cognition Inc. ACOG | Lineage Cell Therapeutics, Inc. LCTX | Pelthos Therapeutics Inc. PTHS | LENZ Therapeutics, Inc. LENZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.22M | $14.56M | $16.80M | $19.09M |
| Revenue growth (YoY) | n/a | +53.2% | n/a | n/a |
| Gross margin | 94.1% (computed) | n/a | 76.3% (computed) | n/a |
| Operating margin | -221.7% | -251.6% | -193.1% | -477.5% |
| Net margin | -202.2% | -436.5% | -257.9% | -430.3% |
| Net income | -$20.67M | -$63.53M | -$43.32M | -$82.13M |
| EPS (Diluted) | -$1.18 | -$0.28 | -$23.04 | -$2.85 |
| Operating cash flow | -$20.38M | -$18.92M | -$22.59M | -$69.17M |
| Free cash flow | -$20.67M | -$19.44M | -$22.69M | -$70.00M |
| Cash & equivalents | $66.05M | $40.79M | $17.97M | $25.18M |
| Total assets | $79.73M | $112.58M | $130.40M | $305.88M |
| Total liabilities | $17.20M | $69.24M | $91.52M | $21.54M |
| Shareholders' equity | $62.53M | $43.35M | $38.88M | $284.34M |
| Return on year-end equity | -33.1% | -146.6% | -111.4% | -28.9% |
| Shares outstanding | 21.74M | 243.12M | 3.23M | 31.34M |
Revenue, most recent five fiscal years
| Fiscal year | Alpha Cognition Inc. | Lineage Cell Therapeutics, Inc. | Pelthos Therapeutics Inc. | LENZ Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $10.22M Ended 2025-12-31 | $14.56M Ended 2025-12-31 | $16.80M Ended 2025-12-31 | $19.09M Ended 2025-12-31 |
| 1 year earlier | n/a | $9.50M Ended 2024-12-31 | $0 Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $8.95M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $14.70M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $4.34M Ended 2021-12-31 | n/a | n/a |